Potential lipid-based strategies of amphotericin B designed for oral administration in clinical application

Abstract

Amphotericin B (AmB) is regarded as a first-line therapy against life-threatening invasive fungal infections. Due to its poor oral bioavailability, AmB is restricted to intravenous administration in clinical practice. As science continues to move forward, two lipid-based formulations are successfully developed for oral AmB administration, currently undergoing phase I clinical trials. Encouragingly, lipid-AmB conjugates with emulsions also exhibit a better bioavailability, which may be another strategy to design oral AmB formulation in clinical practice. Thus, this review mainly focused on the two lipid-based formulations in clinical trials, and discussed the potential perspectives of AmB-lipid conjugation-loaded nanocochleates and emulsions.

Keywords:

• AmB
• oral formulation
• clinical application
• cochleates
• encochleates
• emulsions

Authors’ contribution

Z.X.M and Y.J.Q.; writing-original draft preparation; L.H.Y.; drawing the Figures and Tables; Y.Z.W.; writing-review and editing. All authors have read and agreed to the published version of the manuscript.

Disclosure statement

The authors declare no conflict of interest.

Ethical approval statement

NA

Correction Statement

This article has been corrected with minor changes. These changes do not impact the academic content of the article.

Additional information

Funding

No funding